Category: 23828-92-4

《A review on sustained release drug delivery system》 was published in World Journal of Pharmacy and Pharmaceutical Sciences in 2022. These research results belong to Bhandari, Neeraj; Sharma, Shagun; Sharma, Aman; Disha. Safety of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride The article mentions the following:

A review. A Review. Sustained release matrix tablet is formulated mainly by wet granulation or direct compression method or by dispersion of solid particle within solid particle within a porous matrix formed by using different polymers like Polymethyl methacrylate (PMMA), Polyglycolic acid, HPMC etc. The matrix controls the release rate of drug. retardants like HPMC can aid in sustained release and thus they form core excipient of the formulation. The method involves the direct compression of blend of drug, retardant material and additives to formulate a tablet in which the drug is embedded in a matrix core of the retardant, alternatively granulation can be carried out prior to compression. The matrixes used may be of hydrophilic, hydrophobic, mineral, or biodegradable types. The drug release rate can be studied by in-ugs that have been formulated as sustained release matrix tablets are Ambroxol HCl, Nateglinide etc. Thus, sustained release matrix tablets can assure better patient compliance through reduction in total dose and dosage regimen, which can be of great help to treat chronic diseases. The experimental process involved the reaction of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Safety of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) enhances pulmonary surfactant production and stimulates ciliary activity.Safety of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride It promotes mucus clearance, facilitates expectoration and eases productive cough, allowing patients to breathe.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

《Formulation and in-vitro evaluation of taste masked fast dissolving tablets of Ambroxol hydrochloride》 was written by Debbarma, Bimal; Benedict, Sunaina. Reference of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride And the article was included in World Journal of Pharmacy and Pharmaceutical Sciences in 2021. The article conveys some information:

The purpose of the present work was to mask the taste of Ambroxol hydrochloride and to formulate its patient-friendly dosage form. Complexation technique using KYRON -T-114 an ion-exchange resin was used to mask the bitter taste and the drug loading onto the ion-exchange resin was optimized for ratio of drug to resin, effect of pH and effect on soaking time. The resinate was evaluated for taste masking and characterized by FT-IR and DSC. Then the taste-masked drug was formulated into a fast dissolving tablet (FDT). The developed tablets were evaluated for hardness, friability, drug content, weight variation, content uniformity, friability, water absorption ratio, in-vitro disintegration time and in-vitro drug release studies. IR and DSC spectra revealed that there were no possible interactions between the drug and polymer. Maximum loading was obtained at drug- resin ratio 1:2, pH 7, and soaking time 30 min. A successful taste masking of resinate was confirmed by time intensity method. The values of pre-compression parameters evaluated and were within prescribed limits and indicated good free flowing properties. The data obtained of post-compression parameters found superior over conventional formulation. The F3 batch with disintegration time 30.4±0.64 s and dissolution 98.4±2.69 was selected as optimized formulation, This was compared with conventional marketed formulation and was found superior. The obtained results revealed that Ambroxol hydrochloride has been successfully taste masked and formulated into an FDT as a suitable alternative to the conventional tablets.trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Reference of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride) was used in this study.

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) enhances pulmonary surfactant production and stimulates ciliary activity.Reference of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride It promotes mucus clearance, facilitates expectoration and eases productive cough, allowing patients to breathe.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

The author of 《Quality by design approach to develop stability indicating reversed-phase high-performance liquid chromatography method development for ambroxol》 were Ahmad, Sufiyan; Khabiya, Pranit; Au, Tatiya; Bakhshi, Abdurl Raheman. And the article was published in Asian Journal of Pharmaceutical and Clinical Research in 2021. Safety of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride The author mentioned the following in the article:

As per requisition of current regulatory requirements, simple, rapid and sensitive method by 33 factorial quality by design approach was established and validated for Ambroxol (AMB) by reversed-phase high-performance liquid chromatog. (RP-HPLC). A simple RP-HPLC method has been developed and validated with different parameters such as linearity, precision, repeatability, limit of detection (LOD), limit of quantitation (LOQ), accuracy as per International Conference for Harmonisation guidelines (Q2R1). Statistical data anal. was done for data obtained from different aliquots Runs on Agilent Tech. Gradient System with Auto injector, UV diode-array detection and Gradient Detector. Equipped with Reverse Phase (Agilent) C18 column (4.6 mm x 100 mm; 2.5μm), a 20μl injection loop and UV730D Absorbance detector at 244 nm wave length and running chemstation 10.1 software and drugs along with degradants were separated via Methanol: (0.1% orthophosphoric acid) Water (75:25) of pH 3 as mobile phase setting flow rate 0.7 mL/min at ambient temperature the retention time of AMB were found to be 4.85 min. The industrialized method was found linear over the concentration range of 10-50μg/mL for AMB while the LOD and LOQ of AMB was found to be 0.5174-0.2739μg/mL, anal. method that concluded. There are no interfering peaks underperformed degradation conditions. Therefore, a sensitive, robust, accurate, and stability indicating method was developed with high degree of practical utility. In the experimental materials used by the author, we found trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Safety of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) is a mucolytic expectorant and a metabolite of bromhexine.Safety of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride It is used in the treatment of respiratory disorders characterized by viscous or excessive mucus.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

《Design and evaluation of gastroretentive floating matrix tablets of ambroxol hydrochloride》 was published in International Journal of Pharmacy and Biological Sciences in 2019. These research results belong to Gangireddy, Ramana; Kolagani, Apoorva; Priyanka, D. Kameswari; Gayatri, P.. Recommanded Product: trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride The article mentions the following:

Gastro retentive drug delivery is a special approach which remains in the gastric region for a prolonged period to increase gastric residence time and also have the advantage of site-specific drug delivery especially in the upper gastrointestinal tract (GIT) for local or systemic effects. Ambroxol hydrochloride is a systemically active mucolytic agent with a half-life of 3-4 h. It acts by breakdown of acid muco polysaccharide fibers which make the sputum thinner and less viscous as long as treatment is maintained and therefore more easily sputum was removed by coughing. The main aim of the present work is to develop the oral controlled release floating matrix tablets of Ambroxol hydrochloride by direct compression method, using various hydrophilic polymers such as HPMCK100M, Carbopol971P, Polyethylene oxide. FT-IR studies revealed that there was no incompatibility between the drug and polymers used. All the formulations remained buoyant without any disintegration. The formulations F4, F9, F15 have shown the extended drug release close to that of marketed formulation for a period of 12 h. To ascertain the mechanism of drug release in-vitro data was fitted into various release kinetic models like zero order, first order, Higuchi and Peppas. The values indicated the non-fickian diffusion with slow erosion of polymer matrix followed by drug diffusion and resulted in linear drug release profile over a prolonged period of time. The experimental process involved the reaction of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Recommanded Product: trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) enhances pulmonary surfactant production and stimulates ciliary activity.Recommanded Product: trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride It promotes mucus clearance, facilitates expectoration and eases productive cough, allowing patients to breathe.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

The author of 《Drug utilization pattern in paediatric peritonitis》 were Jayakrishnan, S. S.; Kiron, S. S.. And the article was published in World Journal of Pharmacy and Pharmaceutical Sciences in 2020. Recommanded Product: trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride The author mentioned the following in the article:

Peritonitis is defined as inflammation of a portion or all of the parietal and visceral peritoneum. In peritonitis, an infection can rapidly spread into the blood (sepsis) and then to other organs, carrying the risk of multiple organ failure and if left untreated death will occur. The objective of the study was to determine the drug utilization pattern of peritonitis among paediatric population. It was a Descriptive study for a period o6 mo with 115 patients. All paediatric patients diagnosed clin. with peritonitis reporting to the Department of Paediatric Surgery for undergoing treatment. A written informed consent was taken in a prescribed format from the patient/caregiver diagnosed with peritonitis. Patient who met the inclusion criteria were enrolled for the study. All the information relevant to the study was collected from case records and direct interview with the patient / caregiver by the help of a physician. In the study, majority of patients (43.5%) were in the age group of 7-10 years and were males. The drugs were classified into 9 classes, depending on the therapeutic indications. Majority of patients were given drugs belonging to Antibiotics in class I (100%), followed by Antiulcers in class -IV (97.4%). Drugs belonging to class- VI Antiemetics (18.3%) were the least used in the study population. Other categories of drugs in the study population included class – II used as Analgesics and Antipyretics (93.9%), class – VIII as Vitamins (45.2%), class – IX i.e, Miscellaneous drugs (32.2%), class V as Laxatives (29.6%), class VII (27.8%) used as Antiasthmatics and Antispasmodics class III (26.1%). The study is concluded by the demog. and drug utilization pattern in paediatric peritonitis. Drug utilization evaluation played a key role in helping health care system to understand, interrupt and improve the prescribing, administration and use of medications. The results came from multiple reactions, including the reaction of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Recommanded Product: trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) is a mucolytic expectorant and a metabolite of bromhexine.Recommanded Product: trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride It is used in the treatment of respiratory disorders characterized by viscous or excessive mucus.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

The author of 《Analytical method development and validation for the simultaneous estimation of salbutamol sulphate, guaifenesin, and ambroxol hydrochloride by RP-HPLC method in commercial oral liquid dosage form》 were Thangavelu, Prabha; Grace, Arul Caroline; Murugesan, Jagadeeswaran. And the article was published in International Journal of Pharmaceutical Sciences and Research in 2019. SDS of cas: 23828-92-4 The author mentioned the following in the article:

Salbutamol is a bronchodilator, Guaifenesin is an expectorant and Ambroxol is a mucolytic. Combination of these drugs is used in the formulation of cough syrups. In the literature, there is no method reported for the simultaneous estimation of the drugs in oral liquid dosage form. Hence, the present work is aimed to develop reverse phase HPLC method for the simultaneous determination of Salbutamol sulfate (SAL), Guaifenesin (GUA) and Ambroxol hydrochloride (AMB) in oral liquid dosage form and validation of the developed method. The chromatog. separation of the drugs was achieved with the mobile phase system sodium dihydrogen phosphate buffer pH 3.0: acetonitrile: methanol in the ratio of 65:10:25 with the flow rate of 1 mL/min and injection volume 10μL. An Inertsil C8-3 (250 × 4.6 mm, 5μm) column was used, and the detection wavelength was 276 nm. This system produced sharp peaks with good resolution, min. tailing and satisfactory retention times of SAL, GUA and AMB were found to be 3.157, 9.949 and 11.883 min resp. indicating the suitability of the system. The developed method was validated for various parameters accuracy, precision, linearity, robustness, and specificity as per ICH guidelines. After reading the article, we found that the author used trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4SDS of cas: 23828-92-4)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) is a mucolytic expectorant and a metabolite of bromhexine.SDS of cas: 23828-92-4 It is used in the treatment of respiratory disorders characterized by viscous or excessive mucus.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

The author of 《Stability indicating RP-HPLC method for simultaneous determination of H1- histamine receptor antagonist and mucolytic agent in marketed formulation》 were Jayaprakash, M.; Puranik, S. B.; Gowri, R.. And the article was published in International Journal of Pharmacy and Pharmaceutical Research in 2020. Reference of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride The author mentioned the following in the article:

RP-HPLC method has been developed for simultaneous determination of Stability indicating HPLC method was developed for the simultaneous estimation of Ambroxol hydrochloride and Levocetirizine dihydrochloride in marketed formulation. The HPLC system used was SHIMADZU UFLC-2000 Prominence LC20AD SPDM 20A Binary Gradient System with Rheodyne injector 20μL and the column Enable C18 250 x 4.6 mm, 5μm. The mobile phase comprised of Phosphate buffer (pH 3.0): Methanol in the ratio of 20:80 volume/volume and flow rate of 1.0 mL/min with PDA detection at 236 nm produced peaks of Ambroxol hydrochloride and Levocetirizine dihydrochloride in the chromatogram which was well resolved with a retention time of 3.4 min and 4.7 min resp. The developed HPLC method was validated for various parameters like accuracy, precision, specificity, LOD, LOQ, linearity, range, and robustness as per ICH guidelines. The results obtained were well within the acceptance criteria for all the parameters. The proposed method was applied for the simultaneous estimation of Ambroxol hydrochloride and Levocetirizine dihydrochloride in marketed formulations (capsule). The assay results conformed to the label claim of the formulation. Hence the proposed method can be used for the routine anal. of Ambroxol hydrochloride and Levocetirizine dihydrochloride in their marketed capsule dosage formulations. Forced degradation studies were carried out in Acidic medium, Alk. medium, Oxidation condition, Thermal condition, and Photostability condition and it was found that the degradation and the peaks of degraded products did not interfere with the method. Hence the developed and validated HPLC method can be employed for routine anal. of Ambroxol hydrochloride and Levocetirizine dihydrochloride in marketed formulations. The results obtained were within the acceptance criteria for the parameter. The proposed methods were applied for the estimation of Ambroxol hydrochloride and Levocetirizine dihydrochloride in marketed formulations. Hence the proposed method was found to be satisfactory and could be used for the routine anal. of Ambroxol hydrochloride and Levocetirizine dihydrochloride in their marketed capsule dosage formulations. In the experiment, the researchers used trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Reference of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) is a mucolytic expectorant and a metabolite of bromhexine.Reference of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride It is used in the treatment of respiratory disorders characterized by viscous or excessive mucus.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Lee, Sie Huey; Heng, Desmond; Teo, Jeanette W. P.; Toh, Frederick K. Y.; Tan, Reginald B. H. published their research in International Journal of Pharmaceutics (Amsterdam, Netherlands) on December 15 ,2019. The article was titled 《Inhaled mucoactive particles with tailored architecture for enhanced aerodynamicity, stability and efficacy》.Recommanded Product: trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride The article contains the following contents:

In respiratory and genetic disorders such as asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis and cystic fibrosis (CF), the lungs produce excess mucus, resulting in a thickened mass, which clogs up the airways and reduces airflow. Consequently, breathing becomes more difficult. Medications that break down the structure of mucus will be especially useful in managing the early symptoms of these diseases and preventing their progression into the more severe forms. This work therefore seeks to develop an inhaled mucoactive dry powder formulation that is efficacious on multiple fronts. As an innovative step, sodium chloride was used to tailor the surface architecture of ambroxol hydrochloride particles, such that the resulting angular features on the surfaces contributed to the creation of corrugated particles with enhanced aerodynamicity. The optimized spray-dried powder particles were of respirable-size (d50 of 2.85 ± 0.15 μm) and moderately corrugated. When the crystalline powder was dispersed via an Aerolizer inhaler at 60 L/min, it gave a fine particle fraction (FPF) of ∼31%, which was a ten-fold improvement over the unmodified species (i.e. ambroxol hydrochloride alone). Tests on artificial sputum medium (ASM) showed that the optimized formulation was potentially useful in liquefying the mucus, which favorably pointed towards the effectiveness of the formulation. In addition, the formulation was also stable to moisture ingress (up to ∼60% RH) and had good flowability. Hence, the advent of angular adjuvant sodium chloride particles in a mucoactive formulation conferred a three-fold benefit to the product: (1) Improved aerodynamicity and flowability, (2) Enhanced moisture stability and (3) Synergistic mucolytic properties. The experimental part of the paper was very detailed, including the reaction process of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Recommanded Product: trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) is a medication indicated to alleviate chest congestion associated with conditions that include bronchitis, pneumonia, bronchospasm asthma, cough, and allergy.Recommanded Product: trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride Preclinically, ambroxol, the active ingredient of Mucosolvan, has been shown to increase respiratory tract secretion.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Ochowiak, M.; Kasperkowiak, A.; Doligalski, M.; Sosnowski, T. R.; Matuszak, M.; Wlodarczak, S.; Markowska, M.; Krupinska, A.; Jablczynska, K. published their research in International Journal of Pharmaceutics (Amsterdam, Netherlands) on August 15 ,2019. The article was titled 《The thermostated medical jet nebulizer: Aerosol characteristics》.SDS of cas: 23828-92-4 The article contains the following contents:

The sudden expansion of gas at the outlet of the jet (pneumatic) nebulizer significantly reduces the temperature of the solution, which may provoke bronchospasm, therefore it is recommended to use modern pneumatic inhalers equipped with a thermostat or a universal thermal attachment that allow to obtain a higher temperature aerosol, i.e. thermo-aerosol. The research was carried out for model Newtonian fluids. The droplet diameters of the aerosol spray were investigated using a Spraytec aerosol particle size measurement system. Anal. of the obtained results showed that the increase in solution viscosity caused a decrease in mean droplet diameters and prolonged nebulization time. The anal. of exptl. data made it possible to propose a correlation equation describing the mean diameter of the droplets depending on the properties of the liquid and the flow conditions in the thermostated medical nebulizer. The obtained data contributes to a better understanding of the complex liquid atomization process and can be helpful in the design of medical nebulizers and pharmaceutical preparations After reading the article, we found that the author used trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4SDS of cas: 23828-92-4)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) is a mucolytic expectorant and a metabolite of bromhexine.SDS of cas: 23828-92-4 It is used in the treatment of respiratory disorders characterized by viscous or excessive mucus.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

《Stability indicating rp-hplc method for combination of ambroxol hydrochloride and levofloxacin hemihydrate in pharmaceutical formulation》 was published in International Journal of Pharmaceutical Sciences and Research in 2019. These research results belong to Goswami, J. A.; Shah, N. J.. Electric Literature of C13H19Br2ClN2O The article mentions the following:

Ambroxol hydrochloride (AMB) and Levofloxacin hemihydrate (LVF) in combination were separated using Reverse-Phase – High-Performance Liquid Chromatog. (RP-HPLC) method. Mobile phase acetonitrile and 0.05 M potassium di-hydrogen orthophosphate buffer (pH 7.0 adjusted with sodium hydroxide solution) (50: 50, volume/volume) was selected for this chromatog. method. The separation was achieved in Zorbax Eclipse XDB -C18 column with (250 × 4.5 mm i.d), 5μm particle size with a flow rate of 1.0 mL/min. At 248 nm wavelength, 10μl of 60μg/mL Ambroxol hydrochloride and 400μg/mL Levofloxacin hemihydrate (LVF) was injected for 15 min runtime, and an individual peak was obtained for LVF at retention time 2.61 min and for AMB at retention time 7.69 min. Linearity was achieved for Ambroxol hydrochloride in the range of 48 mcg/mL to 72 mcg/mL and Levofloxacin hemihydrate in the range of 320 mcg/mL to 480 mcg/mL. For stress degradation, AMB and LVF were subjected to acid hydrolysis, base hydrolysis, thermal degradation, UV light degradation, oxidation and analyzed with this chromatog. method. The results obtained with this method are useful for assay of this pharmaceutical formulation; hence this method can be used in the pharmaceutical industry.trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Electric Literature of C13H19Br2ClN2O) was used in this study.

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) enhances pulmonary surfactant production and stimulates ciliary activity.Electric Literature of C13H19Br2ClN2O It promotes mucus clearance, facilitates expectoration and eases productive cough, allowing patients to breathe.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts